<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="3644"><DrugName>moclobemide</DrugName><DrugNamesKey><Name id="42766457">Maclamine</Name><Name id="42810668">moclobemide</Name></DrugNamesKey><DrugSynonyms><Name><Value>Maclamine</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>moclobemide</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>Aurorix</Value></Name><Name><Value>Manerix</Value></Name><Name><Value>Moclaime</Value></Name><Name><Value>Ro-11-1163</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Ro-11-1163/000</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>71320-77-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19446">Roche Holding AG</CompanyOriginator><CompaniesPrimary><Company id="19446">Roche Holding AG</Company><Company id="30001">Meda Pharmaceuticals Ltd</Company><Company id="19466">Produits Roche SA</Company></CompaniesPrimary><CompaniesSecondary><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3644" type="Drug"><TargetEntity id="90662" type="siDrug">Moclobemide</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="19466" type="Company"><TargetEntity id="4296460457" type="organizationId">Roche SAS</TargetEntity></SourceEntity><SourceEntity id="30001" type="Company"><TargetEntity id="4298522621" type="organizationId">Meda Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"/><TargetEntity id="D001008" type="MeSH"/><TargetEntity id="-1384065283" type="omicsDisease"/><TargetEntity id="30" type="siCondition"/></SourceEntity><SourceEntity id="282" type="ciIndication"><TargetEntity id="10061920" type="MEDDRA"/><TargetEntity id="D011618" type="MeSH"/><TargetEntity id="61" type="siCondition"/></SourceEntity><SourceEntity id="3150" type="ciIndication"><TargetEntity id="F40.1" type="ICD10"/><TargetEntity id="10041250" type="MEDDRA"/><TargetEntity id="-999270457" type="omicsDisease"/><TargetEntity id="36" type="siCondition"/></SourceEntity><SourceEntity id="90" type="ciIndication"><TargetEntity id="10012267" type="MEDDRA"/><TargetEntity id="D003704" type="MeSH"/><TargetEntity id="-1720562635" type="omicsDisease"/><TargetEntity id="100" type="siCondition"/></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="254" type="Action"><TargetEntity id="449" type="Mechanism">MAO-A Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01273" type="ciTarget"><TargetEntity id="175834908241283" type="siTarget">Amine oxidase [flavin-containing] A</TargetEntity><TargetEntity id="9251" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Depression - Sweden - Jan-1989</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="14">Alzheimers disease</Indication><Indication id="25">Anxiety disorder</Indication><Indication id="282">Psychotic disorder</Indication><Indication id="3150">Social phobia</Indication><Indication id="90">Dementia</Indication><Indication id="93">Depression</Indication></IndicationsPrimary><ActionsPrimary><Action id="254">MAO A inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="2942">Anxiolytic</Action><Action id="2943">Antipsychotic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-27T11:13:44.000Z</LastModificationDate><ChangeDateLast>2018-09-11T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt; has launched moclobemide, an MAO-A inhibitor,  as an antidepressant. The product has been launched in the US, UK, and Europe by mid-1990s. In February 1990, the drug was approved in Denmark and was subsequently launched [&lt;ulink linkID="1425614" linkType="Reference"&gt;1425614&lt;/ulink&gt;]. In October 1990, the drug was approved in Iceland [&lt;ulink linkID="1450881" linkType="Reference"&gt;1450881&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. In May 1991, the drug was approved in Czech Republic [&lt;ulink linkID="1444860" linkType="Reference"&gt;1444860&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]. In June 1991, the drug was approved in the Netherlands [&lt;ulink linkID="1428869" linkType="Reference"&gt;1428869&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1428871" linkType="Reference"&gt;1428871&lt;/ulink&gt;]. In February 1992, &lt;ulink linkID="30001" linkType="Company"&gt;Meda Pharmaceuticals&lt;/ulink&gt; received approval to market the drug in Spain, and subsequently launched the product as Manerix [&lt;ulink linkID="1362910" linkType="Reference"&gt;1362910&lt;/ulink&gt;].  In January 2001, the drug was launched in Norway [&lt;ulink linkID="1458044" linkType="Reference"&gt;1458044&lt;/ulink&gt;]. In October 2006, the drug was launched as Aurorix in Portugal for social phobia and depressive syndromes [&lt;ulink linkID="1385191" linkType="Reference"&gt;1385191&lt;/ulink&gt;]. By November 2018, Manerix was launched in Ireland by &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; [&lt;ulink linkID="2134960" linkType="Reference"&gt;2134960&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15606" linkType="Company"&gt;Dainippon&lt;/ulink&gt; was conducting phase II trials in Japan for depression [&lt;ulink linkID="358361" linkType="reference"&gt;358361&lt;/ulink&gt;], [&lt;ulink linkID="487157" linkType="reference"&gt;487157&lt;/ulink&gt;]. However, no development has been reported since 2000 [&lt;ulink linkID="377549" linkType="Reference"&gt;377549&lt;/ulink&gt;]. Dainippon was also developing the compound for use in social phobias [&lt;ulink linkID="358361" linkType="reference"&gt;358361&lt;/ulink&gt;], [&lt;ulink linkID="487157" linkType="reference"&gt;487157&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;Moclobemide was launched in the US, UK, and Europe by the mid-1990s [&lt;ulink linkID="358361" linkType="reference"&gt;358361&lt;/ulink&gt;], [&lt;ulink linkID="487157" linkType="reference"&gt;487157&lt;/ulink&gt;]. In February 1990, the drug was approved in Denmark and was subsequently launched [&lt;ulink linkID="1425614" linkType="Reference"&gt;1425614&lt;/ulink&gt;]. In October 1990, the drug was approved in Iceland [&lt;ulink linkID="1450881" linkType="Reference"&gt;1450881&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. In May 1991, the drug was approved in Czech Republic [&lt;ulink linkID="1444860" linkType="Reference"&gt;1444860&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]. In June 1991, the drug was approved in the Netherlands [&lt;ulink linkID="1428869" linkType="Reference"&gt;1428869&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1428871" linkType="Reference"&gt;1428871&lt;/ulink&gt;]. In July 1991, Manerix was approved in Ireland [&lt;ulink linkID="1397721" linkType="Reference"&gt;1397721&lt;/ulink&gt;]. In February 1992, Meda Pharmaceuticals received approval to market the drug in Spain, and subsequently launched it as Manerix  [&lt;ulink linkID="1362910" linkType="Reference"&gt;1362910&lt;/ulink&gt;]. In January 2001, the drug was launched in Norway [&lt;ulink linkID="1458044" linkType="Reference"&gt;1458044&lt;/ulink&gt;].  In October 2006, the drug was launched as Aurorix in Portugal for social phobia and depressive syndromes [&lt;ulink linkID="1385191" linkType="Reference"&gt;1385191&lt;/ulink&gt;]. By November 2018, Manerix was launched in Ireland [&lt;ulink linkID="2134960" linkType="Reference"&gt;2134960&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;Roche has launched moclobemide in Russia as Aurorix, for the treatment of depressive symptoms and social phobia [&lt;ulink linkID="1383834" linkType="Reference"&gt;1383834&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The compound was first described in the associated patent, AT-00349480, as a monoamine oxidase inhibitor. &lt;ulink linkID="19461" linkType="Company"&gt;Hoffmann-La Roche&lt;/ulink&gt; holds another patent, &lt;ulink linkID="IN1478936" linkType="Patent"&gt;US-04906626&lt;/ulink&gt;, where its use in the treatment of cognitive impairment, especially that associated with senescence, is claimed.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2001-01-01T00:00:00.000Z</StatusDate><Source id="1458044" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1993-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2006-10-01T00:00:00.000Z</StatusDate><Source id="1385191" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="1425614" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1991-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2018-11-05T00:00:00.000Z</StatusDate><Source id="2134960" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><Source id="1450511" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1989-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="90">Dementia</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="1362910" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3150">Social phobia</Indication><StatusDate>2006-10-01T00:00:00.000Z</StatusDate><Source id="1385191" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3150">Social phobia</Indication><Source id="1383834" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1995-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="1444818" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="1428871" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1991-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1990-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1990-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="1383834" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1991-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19466">Produits Roche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1995-05-01T00:00:00.000Z</StatusDate><Source id="177559" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2002-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1992-02-01T00:00:00.000Z</StatusDate><Source id="1362910" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1990-02-28T00:00:00.000Z</StatusDate><Source id="1425614" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1991-06-14T00:00:00.000Z</StatusDate><Source id="1428869" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1991-05-22T00:00:00.000Z</StatusDate><Source id="1444860" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1990-10-01T00:00:00.000Z</StatusDate><Source id="1450881" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30001">Meda Pharmaceuticals Ltd</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1991-07-04T00:00:00.000Z</StatusDate><Source id="1397721" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1999-03-01T00:00:00.000Z</StatusDate><Source id="358361" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01273"><Name>MAO A</Name><SwissprotNumbers><Swissprot>O18851</Swissprot><Swissprot>P21396</Swissprot><Swissprot>P21397</Swissprot><Swissprot>P21398</Swissprot><Swissprot>P58027</Swissprot><Swissprot>Q5NU32</Swissprot><Swissprot>Q5RE60</Swissprot><Swissprot>Q64133</Swissprot><Swissprot>Q6Q2J0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2065599" linkType="reference" linkID="2065599"&gt;2065599&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1071457">Eastpharma Group</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18439">Mylan NV</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cc(ccc1C(=O)NCCN2CCOCC2)Cl</Smiles></StructureSmiles><Deals><Deal id="114696" title="Meda to develop widely launched pharmaceutical products from Roche"/><Deal id="115280" title="Meda and Valeant to form Meda Valeant Pharma joint ventures in Australia, Canada and Mexico for various drugs"/><Deal id="249251" title="Eastpharma acquires Roche's products registered in Turkey  "/></Deals><PatentFamilies><PatentFamily id="1192124" number="IN-200100466" title="Preparation of pharmaceutical composition useful for controlled release of moclobemide, by mixing moclobemide or its salts and excipients, forming into core and optionally coating"/><PatentFamily id="172061" number="WO-09952504" title="Process For The Manufacture Of (Sub)Micron Sized Particles By Dissolving In Compressed Gas And Surfactants"/><PatentFamily id="2154786" number="WO-2012083493" title="Medicinal composition"/><PatentFamily id="2366242" number="RU-02414462" title="Method for preparing 4-chlor-N-(2-morpholinoethyl)benzamide"/><PatentFamily id="2602000" number="CN-103040836" title="Anti-prostate cancer use and medicine preparation of moclobemide"/><PatentFamily id="411548" number="WO-09913878" title="A combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist."/><PatentFamily id="420179" number="EP-01731156" title="Pharmaceutical compositions to treat or prevent cerebral oedema"/><PatentFamily id="620334" number="US-04210754" title="Morpholino Containing Benzamides"/><PatentFamily id="642272" number="WO-2004089351" title="Methods and means for the treatment of progressive neurological disorders"/><PatentFamily id="663641" number="CN-101987198" title="Pharmaceutical composition"/><PatentFamily id="716828" number="WO-00006138" title="Methods and compositions for using moclobemide."/><PatentFamily id="721104" number="WO-00006139" title="Methods and compositions for treating and preventing substance abuse using moclobemide."/><PatentFamily id="834033" number="WO-09528934" title="Use of MAO-A inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers."/><PatentFamily id="841147" number="GB-01512194" title="Benzamides"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Organic Intermediates &amp; Dye Stuffs Inst" id="1006724"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Meibeita Drug Res Co Ltd" id="1071181"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratoires Biocodex" id="14694"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmos Corp" id="19072"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Cambridge" id="20550"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="aRigen Pharmaceuticals Inc" id="30124"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>